Arcus Biosciences Inc
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
RCUS$18.67-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flow from operating activities | |||
| Net income (loss) | $(307) | $(267) | $53 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||
| Stock-based compensation expense | 73 | 65 | 55 |
| Depreciation and amortization | 8 | 6 | 4 |
| Noncash lease expense | 8 | 8 | 3 |
| Amortization of premiums (discounts) on marketable securities | (19) | — | 5 |
| Other items, net | 2 | 3 | — |
| Changes in operating assets and liabilities: | |||
| Receivable from collaboration partners ($19, $704 and ($17) from a related party) | 15 | 704 | (17) |
| Other assets (($4), ($2) and $— from a related party) | (14) | 2 | (3) |
| Accounts payable | (1) | 8 | (5) |
| Deferred revenue (($77), ($107) and ($361) to a related party) | (68) | (112) | (368) |
| Other liabilities | (3) | 21 | 17 |
| Net cash provided by (used in) operating activities | (306) | 438 | (256) |
| Cash flow from investing activities | |||
| Purchases of marketable securities | (788) | (1,241) | (719) |
| Proceeds from maturities of marketable securities | 982 | 694 | 690 |
| Proceeds from sales of marketable securities | 24 | 143 | 51 |
| Purchases of property and equipment | (24) | (6) | (26) |
| Purchases of in-process research and development | — | (6) | — |
| Collaboration reimbursements of in-process research and development from a related party | — | 3 | — |
| Net cash provided by (used in) investing activities | 194 | (413) | (4) |
| Cash flow from financing activities | |||
| Proceeds from issuance of common stock ($20, $— and $220 from a related party) | 25 | — | 220 |
| Proceeds from issuance of common stock pursuant to equity award plans | 8 | 23 | 12 |
| Proceeds from sale of future royalties | — | 10 | 5 |
| Net cash provided by financing activities | 33 | 33 | 237 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (79) | 58 | (23) |
| Cash, cash equivalents and restricted cash at beginning of period | 209 | 151 | 174 |
| Cash, cash equivalents and restricted cash at end of period | $130 | $209 | $151 |
| Supplemental disclosure of cash flow information | |||
| Income taxes paid | $5 | $3 | $— |
| Non-cash investing and financing activities: | |||
| Unpaid portion of property and equipment purchases included in Accounts payable and Other current liabilities | $2 | $3 | $1 |
| Unpaid portion of other assets included in accrued research and development | $— | $— | $1 |
| Vesting of early exercised stock options and restricted stock | $— | $— | $1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.